

The need to know facts about Invasive Meningococcal Disease



Invasive meningococcal disease can be **easily misdiagnosed**^{1,2}


While rare, it can have serious consequences including: **long-term disability**^{3,4}



Potential death within **24 hours** after the onset of symptoms^{2,6}




Even with appropriate treatment, as many as **10%** of people with meningococcal disease will die^{7,8}




Almost **1 in 5** survivors will suffer long-term disability^{3,4}

Group B

is one of the most prevalent groups in the US⁵



There are five main groups of meningococcal bacteria (**A, B, C, W-135** and **Y**) that cause the majority of cases around the world. Until recently, vaccines were only available to help protect against groups A, C, W-135 and Y in the US. Groups B, C and Y cause the majority of cases in the US⁷.



The US Centers for Disease Control and Prevention (CDC) estimates that **600 to 1,000** Americans contract meningococcal disease each year⁹

Adolescents and young adults are at risk of contracting meningococcal disease due to social factors, such as living in college dormitories⁷



- References:
1. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. *New England Journal of Medicine (NEJM)*. 2001;344:1378-1388.
 2. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. *Lancet*. 2006;367(9508):397-403.
 3. Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococemia: a review and recent experience. *Pediatric Infectious Disease Journal*. 1996;15:967-79.
 4. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. *Journal of Pediatrics*. 1981;99:540-5.
 5. Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network – Neisseria meningitidis, 2013, provisional. Available at: <http://www.cdc.gov/abc/reports-findings/survreports/mening13.pdf>. Accessed January 2015.
 6. de Greeff SC, de Melker HE, Schouls LM, Spanjaard L, van Deuren M. Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003–2005. *European Journal of Clinical Microbiology & Infectious Diseases*. 2008;27:985-992.
 7. Centers for Disease Control and Prevention (CDC). Prevention and Control of Meningococcal Disease; Recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity and Mortality Weekly Report (MMWR)*. 2013; 62(2):1-13. Available at: <http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf>. Accessed January 2015.
 8. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. *Clinical Infectious Diseases*. 2010; 50:184–91.
 9. Centers for Disease Control and Prevention (CDC). "Help Protect Your Preteen and Teen Against Meningococcal Disease." April 21, 2014. Available at: <http://www.cdc.gov/features/meningococcal/>. Accessed January 2015.